ECTRIMS 2024: Simvastatin fails to slow disability progression in SPMS
Daily treatment with high-dose simvastatin, a widely used cholesterol-lowering medication, failed to slow disability progression in adults with secondary progressive disease or SPMS, according to top-line data from a Phase 3 clinical study. Jeremy Chataway, PhD, a professor of neurology at University College London (UCL) in the U.K.,…